HAMBURG, GERMANY - A new study led by precision oncology pioneers Indivumed Therapeutics reveals significant changes in the molecular characteristics of tumor samples within as little as 10 minutes after surgical removal. The findings underline the importance of rapid snap freezing of tissue samples to reliably capture cancer biology and reveal novel drug targets.
Publishing in Cell Death & Disease, the study analyzed the impact of cold ischemia time (the time it takes to preserve surgically removed tissue) on more than 1,800 tumor and matched normal tissue samples across four cancer…
• Programmable, tunable, stable and specific gene silencing has been demonstrated across multiple target genes and multiple cell types
• PoC achieved with concomitant silencing of more than one gene
• Industrialisation of platform processes delivering significant increase in throughput
• Strategic in-house focus on development of pipeline of programmable advanced therapies in oncology and genetic disease
• Potential additional application to multiple high impact therapeutic areas through partnering including, hypoimmunogenicity/type 1 diabetes, inflammatory diseases and fibrosis
Stevenage,…
London, September 26, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with CellCentric and is pleased to announce the placement of Andy Fergus as Chief Development Officer. Andy joined CellCentric in September 2024, and is Boston based.CellCentric’s mission is to transform outcomes for people living with specific cancers, notably relapsed refractory multiple myeloma, as quickly and effectively as possible. The clinical-stage biotech company focuses on the development of inobrodib,…
PACE (Pathways to Antimicrobial Clinical Efficacy) has today launched its second funding round with up to £5 million available to support cutting-edge diagnostic projects. This funding is part of a broader £30 million investment to address the global challenge of antimicrobial resistance (AMR).
PACE is one of the UK’s largest public-private initiatives targeting early-stage antimicrobial drug and diagnostic discovery. The pioneering partnership between LifeArc, Medicines Discovery Catapult (MDC) and Innovate UK is driving the development of new tests and treatments to tackle deadly AMR, which…
Paris, France - A new research study published in Nature Communications highlights how Depixus’ scalable single molecule technology can provide detailed mechanistic insights into RNA-ligand binding, supporting the development of novel therapeutics.
Based on magnetic force spectroscopy (MFS), Depixus’ large scale interactomics platform is the first analytical technology capable of exploring dynamic biomolecular interactions both in real time and from thousands of individual molecules in parallel.
The study was led by Dr. John “Jay” Schneekloth, Jr. a leading expert in RNA-targeted drug…
Oxford, UK - British techbio innovator Etcembly has launched a groundbreaking new research study aiming to uncover new targets for cancer therapies by analysing the immune cells of cancer survivors.
The ETCh study is recruiting people aged 18-65 who are living with or have survived cancer to join the study, as well as healthy volunteers. Participants will be asked to donate a small amount of blood up to five times over the course of one year, and provide information about their health.
The ETCh study is rooted in the well-established concept that long-term survivors have beaten cancer due to…
We invite you to join us for an afternoon in Cambridge MA, where we’ll be hosting an exclusive hands-on workshop featuring the latest release of Cresset’s ligand and structure-based drug design platform, Flare™. During this interactive session, you’ll explore key topics such as:
• Rapid approaches to new scaffold generation
• Qualitative analysis of structure-activity relationships (SAR)
Following the workshop, we will delve into how digital transformation is reshaping the industry and explore the ways in which Cresset is helping to catalyze that change.
Afterwards, please join us for a…
AMSBIO has launched CellO-IF – an all-in-one immunofluorescent staining reagent kit designed to accelerate the labelling organoids and spheroids directly in hydrogels or extracellular matrices, while preserving delicate structures and cellular integrity.
Immunofluorescence (IF) allows detection and localization of antigens in diverse types of tissues in various cell preparations. The technique provides excellent sensitivity and amplification of signal by comparison to immunohistochemistry. However, traditional IF staining is a labor intensive, multi-step…
Recent research indicates that the rate of global warming caused by human activity is at an all-time high.* In response, Pioneer Group, a specialist in life science infrastructure and venture building, is ramping up its support for start-up businesses tackling planetary health challenges.
This year, Pioneer is accelerating the development of planetary health innovations through a comprehensive programme of events, a “Golden Ticket” competition, venture development support, specialist lab space, and access to its expert network.
“With global temperatures on the rise, supporting innovations…